Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
On July 20, Halozyme Therapeutics, Inc.
Incyte Corp (INCY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 30,762,330 | $3,487,217,729 | +1% | 17.48% |
| 2. | AQR Capital Management Cliff Asness | 5,320,901 | $603,177,347 | -9% | 0.21% |
| 3. | Renaissance Technologies Jim Simons | 3,512,132 | $398,135,284 | -4% | 0.55% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,744,958 | $311,168,439 | -4% | 0.14% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,310,154 | $148,519,056 | +5% | 0.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $73.31 | 175,795 | $12,887,302.92 | 33,419,055 | 2022-03-10 | Filing | |
| $73.31 | 14,490 | $1,062,243.06 | 2,941,147 | 2022-03-10 | Filing | |
| $71.95 | 1,017 | $73,176.91 | 33,243,260 | 2022-03-10 | Filing | |
| $71.95 | 84 | $6,044.11 | 2,926,657 | 2022-03-10 | Filing | |
| $71.90 | 25,107 | $1,805,125.51 | 33,242,243 | 2022-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $125.56 | 10,801 | $1,356,173.56 | 183,200 | 2026-08-19 | Filing | |
| $120.04 | 10,803 | $1,296,792.12 | 194,001 | 2026-08-12 | Filing | |
| $122.69 | 10,640 | $1,305,421.60 | 204,804 | 2026-08-05 | Filing | |
| $123.99 | 2,207 | $273,645.93 | 61,441 | 2026-08-05 | Filing | |
| $119.70 | 15,888 | $1,901,793.60 | 215,444 | 2026-07-31 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,032,718 | $2,044,188,907 | 0.03% | |
| 2. | 11,957,326 | $1,355,482,475 | 0.71% | |
| 3. | 11,024,289 | $1,249,713,401 | 0.03% | |
| 4. | 9,722,336 | $1,102,124,009 | 0.03% | |
| 5. | 7,791,091 | $883,198,076 | 0.04% |
News See All
Leaving Estimates in the Dust: 28 Firms Beating Earnings Expectations
Research from Morgan Stanley showed that the median EPS surprise for S&P 500 companies reached 6% in the first quarter of 2026, the strongest reading in four years and above the long-run average of around...
Billionaire Cliff Asness’ Top 10 Healthcare Stock Picks
Cliff Asness is a billionaire investor and the co-founder and chief investment officer of AQR Capital Management, a quantitative hedge fund.
Incyte Corporation (INCY) Highlights Sustained Efficacy of Opzelura Through Week 24
On May 7, INCY reported final 24-week results from its Phase 3 TRuE-AD4 study evaluating Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis who had limited response or intolerance ...
10 Best Cancer Stocks to Buy for the Long Term
Pharmaceutical firms have always had a special place in the healthcare market because they provide stability and expansion.
Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock Ratings
Incyte Corporation (NASDAQ:INCY) ranks among the most profitable biotech stocks to buy now. On April 15, H.C. Wainwright restated Incyte Corporation (NASDAQ:INCY)’s Buy rating and $135 price target.
10 Most Profitable Biotech Stocks to Buy Now
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, surpassing both the S&P 500 and the broader market index, and ending 2025 with its...
Incyte Corporation (NASDAQ:INCY) Q1 2026 Earnings Call Transcript
Operator: Greetings, and welcome to the Incyte First Quarter 2026 Earnings Conference Call Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
RBC Capital Lifts PT on Incyte Corporation (INCY) to $95 From $92
Incyte Corporation (NASDAQ:INCY) is one of the most undervalued biotech stocks to buy right now. RBC Capital raised the price target on Incyte Corporation (NASDAQ:INCY) to $95 from $92 on April 7, reiterating...
8 Most Undervalued Biotech Stocks to Buy Right Now
On April 13, Tom Lee, Fundstrat's head of research, appeared on CNBC’s 'Power Lunch' to talk about his outlook on equities, what to expect in a wartime economy, and more.
Hedge Fund Resource Center